The breaking news
Veteran biotech writer Adam Feuerstein, with Matthew Herper, reported for STAT after-hours Thursday on Gilead's (GILD) high-profile investigational antiviral, setting off bullish trading in GILD and in all major US stock market indices. The article's lede sets the basic story:
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than